Angioplasty for the erectile dysfunction

Original title: Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects With Suboptimal Response to Phosphodiesterase-5 Inhibitors. Reference: Jason H. Rogers et al. J Am Coll Cardiol 2012. Article in press

Up to 52% of men between 40 – 70 years old present some degree of erectile dysfunction, and 50% of these men get a suboptimal response to sildenafil treatments.  Coronary disease and erectile dysfunction share risk factors. In fact, 70% of men with documented coronary disease have erectile dysfunction. 

Since balloon angioplasty has shown benefits, at least in the short term, this study was performed for the first time in men to assess the safety and feasibility of Zotarolimus DES in the treatment of erectile dysfunction with suboptimal response to sildenafil (ZEN trial).

Main inclusion criteria were insufficient response to sildenafil, reduced flow of the cavernosal artery at Doppler examination, and a severe lesion in one or both pudendal arteries at angiographic examination. 

The International Index for Erectile Dysfunction, already validated by previous studies, was used to make comparisons before and after procedure. Primary safety end point was any adverse event at 30 days and feasibility end point was improvement of the International Index for Erectile Dysfunction at 3 months.

89 patients were considered, 30 of them finally fulfilled all criteria and received angioplasty with Zotarolimus eluting Resolute stent implantation in their pudendal artery (Medtronic, Santa Rosa, California). All patients reached the safety end point at 30 days and did not present adverse events at 6 months.

At 3 months, 68,3% of patients presented improvement of erectile dysfunction according to the International Index which continued at 6 months. A Doppler ultrasound showed the concurrent increase of penile flow. Binary restenosis at 6 months was 34,4%.

Conclusion 

Angioplasty to the internal pudendal artery with Zotarolimus eluting stent implantation in patients with suboptimal response to sildenafil is safe and feasible; it can increase penile flow and improve erectile dysfunction.

Editorial Comment:

The absence of a control group and the small and selected population enrolled are limitations to this study. The International Index of Erectile Dysfunction, though valid, relies on multiple subjective parameters in patients that were not blind to the treatment they had received. It is also noted the difference in binary restenosis of the pudendal internal artery compared to a coronary of same diameter with the same device. Despite the above mentioned, the population that could benefit from this procedure is much larger than we believe, especially taking into account the absence of adverse events.

SOLACI.ORG

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...